ACA
LXEO icon

Avoro Capital Advisors’s Lexeo Therapeutics LXEO Stock Holding History

Avoro Capital Advisors’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.93M Sell
1,489,189
-385,811
-21% -$2.09M 0.06% 26
2026
Q1 		$10.8M Sell
1,875,000
-1,425,000
-43% -$10.1M 0.11% 28
2025
Q4 		$32.8M Buy
+3,300,000
New +$30.1M 0.32% 29

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Avoro Capital Advisors's LXEO Position: Q2 2026 in Review

Avoro Capital Advisors reduced its Lexeo Therapeutics (LXEO) stake by 21% in Q2 2026, selling an estimated $2.09M and leaving 1,489,189 shares worth $6.93M. The position accounts for 0.06% of the portfolio, ranked #26.

Avoro Capital Advisors first reported a position in LXEO in Q4 2025 and has held it in 3 quarters since. The position peaked at $32.8M in Q4 2025. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Avoro Capital Advisors held 1,489,189 shares of Lexeo Therapeutics worth $6.93M as of Q2 2026.
  • Avoro Capital Advisors sold 385,811 Lexeo Therapeutics shares in Q2 2026, an estimated $2.09M.
  • Lexeo Therapeutics made up 0.06% of Avoro Capital Advisors's portfolio in Q2 2026, its #26 holding.
  • Avoro Capital Advisors first reported a position in Lexeo Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Avoro Capital Advisors's Lexeo Therapeutics position peaked at $32.8M in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Avoro Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.